ID   VDE_SPIOL               Reviewed;         472 AA.
AC   Q9SM43;
DT   23-JAN-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 2.
DT   02-DEC-2020, entry version 75.
DE   RecName: Full=Violaxanthin de-epoxidase, chloroplastic {ECO:0000303|Ref.2};
DE            EC=1.23.5.1 {ECO:0000269|Ref.1, ECO:0000269|Ref.2};
DE   Flags: Precursor;
GN   Name=VDE1 {ECO:0000303|Ref.2}; Synonyms=SVDE1;
OS   Spinacia oleracea (Spinach).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; eudicotyledons; Gunneridae; Pentapetalae;
OC   Caryophyllales; Chenopodiaceae; Chenopodioideae; Anserineae; Spinacia.
OX   NCBI_TaxID=3562;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], MUTAGENESIS OF HIS-245; HIS-248; HIS-291 AND
RP   HIS-297, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Leaf;
RX   DOI=10.1034/j.1399-3054.2003.00151.x;
RA   Emanuelsson A.K., Eskling M., Aakerlund H.-E.;
RT   "Chemical and mutational modification of histidines in violaxanthinde-
RT   epoxidase from Spinacia oleracea.";
RL   Physiol. Plantarum 119:97-104(2003).
RN   [2]
RP   PROTEIN SEQUENCE OF 125-144, AND CATALYTIC ACTIVITY.
RX   DOI=10.1007/BF00117662;
RA   Arvidsson P.-O., Bratt C.E., Carlsson M., Aakerlund H.-E.;
RT   "Purification and identification of the violaxanthin deepoxidase as a 43
RT   kDa protein.";
RL   Photosyn. Res. 49:119-129(1996).
RN   [3]
RP   SUBCELLULAR LOCATION, ACTIVITY REGULATION, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   DOI=10.1007/BF00203597;
RA   Hager A., Holocher K.;
RT   "Localization of the xanthophyll-cycle enzyme violaxanthin de-epoxidase
RT   within the thylakoid lumen and abolition of its mobility by a (light-
RT   dependent) pH decrease.";
RL   Planta 192:581-589(1994).
RN   [4]
RP   SUBCELLULAR LOCATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   DOI=10.1007/BF00032588;
RA   Bratt C.E., Arvidsson P.-O., Carlsson M., Aakerlund H.-E.;
RT   "Regulation of violaxanthin de-epoxidase activity by pH and ascorbate
RT   concentration.";
RL   Photosyn. Res. 45:169-175(1995).
RN   [5]
RP   ACTIVITY REGULATION.
RX   DOI=10.1023/A:1005868026374;
RA   Arvidsson P.-O., Carlsson M., Stefansson H., Albertsson P.-A.,
RA   Aakerlund H.-E.;
RT   "Violaxanthin accessibility and temperature dependency for de-epoxidation
RT   in spinach thylakoid membranes.";
RL   Photosyn. Res. 52:39-48(1997).
RN   [6]
RP   ACTIVITY REGULATION.
RX   PubMed=16228481; DOI=10.1023/a:1006496719927;
RA   Pan R.-S., Dilley R.A.;
RT   "Influence of Ca(2+) on the thylakoid lumen violaxanthin de-epoxidase
RT   activity through Ca(2+) gating of H(+) flux at the CF(o) H(+) channel.";
RL   Photosyn. Res. 65:141-154(2000).
RN   [7]
RP   ACTIVITY REGULATION.
RX   PubMed=15078086; DOI=10.1021/bi049652g;
RA   Latowski D., Aakerlund H.-E., Strzalka K.;
RT   "Violaxanthin de-epoxidase, the xanthophyll cycle enzyme, requires lipid
RT   inverted hexagonal structures for its activity.";
RL   Biochemistry 43:4417-4420(2004).
RN   [8]
RP   ACTIVITY REGULATION.
RX   PubMed=17618598; DOI=10.1016/j.bbamem.2007.06.001;
RA   Szilagyi A., Sommarin M., Akerlund H.E.;
RT   "Membrane curvature stress controls the maximal conversion of violaxanthin
RT   to zeaxanthin in the violaxanthin cycle--influence of alpha-tocopherol,
RT   cetylethers, linolenic acid, and temperature.";
RL   Biochim. Biophys. Acta 1768:2310-2318(2007).
RN   [9]
RP   MUTAGENESIS OF CYS-131; CYS-133; CYS-138; CYS-145; CYS-151; CYS-157;
RP   CYS-161; CYS-170; CYS-174; CYS-189; CYS-196; CYS-242 AND CYS-372, AND
RP   DISULFIDE BOND.
RX   PubMed=25764016; DOI=10.1007/s11120-015-0118-9;
RA   Hallin E.I., Guo K., Aakerlund H.E.;
RT   "Violaxanthin de-epoxidase disulphides and their role in activity and
RT   thermal stability.";
RL   Photosyn. Res. 124:191-198(2015).
CC   -!- FUNCTION: Part of the xanthophyll (or violaxanthin) cycle for
CC       controlling the concentration of zeaxanthin in chloroplasts. Catalyzes
CC       the two-step mono de-epoxidation reaction. Stereospecific for all-trans
CC       xanthophylls. Zeaxanthin induces the dissipation of excitation energy
CC       in the chlorophyll of the light-harvesting protein complex of
CC       photosystem II.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=all-trans-violaxanthin + 2 L-ascorbate = all-trans-zeaxanthin
CC         + 2 H2O + 2 L-dehydroascorbate; Xref=Rhea:RHEA:32371,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:27547, ChEBI:CHEBI:35288,
CC         ChEBI:CHEBI:38290, ChEBI:CHEBI:58539; EC=1.23.5.1;
CC         Evidence={ECO:0000269|Ref.1};
CC   -!- ACTIVITY REGULATION: Irreversibly inhibited by DTT and iodoacetamide at
CC       pH 5.7 or pH 5.2, but not at pH 7.2 (Ref.5, Ref.3). Regulated through
CC       Ca(2+) gating of H(+) flux at the CFoH(+) channel (PubMed:16228481).
CC       Requires the presence of lipids forming reverse hexagonal structures
CC       such as monogalactosyldiacylglyceride (MGDG) or
CC       phosphatidylethanolamine (PubMed:15078086). A negative curvature
CC       elastic stress in the thylakoid lipid bilayer is required for VDE1
CC       activity (PubMed:17618598). {ECO:0000269|PubMed:15078086,
CC       ECO:0000269|PubMed:16228481, ECO:0000269|PubMed:17618598,
CC       ECO:0000269|Ref.3, ECO:0000269|Ref.5}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=10 mM for ascorbate at pH 6.0 {ECO:0000269|Ref.4};
CC         KM=2.5 mM for ascorbate at pH 5.5 {ECO:0000269|Ref.4};
CC         KM=1 mM for ascorbate at pH 5.0 {ECO:0000269|Ref.4};
CC         KM=0.3 mM for ascorbate at pH 4.5 {ECO:0000269|Ref.4};
CC         Note=KM for ascorbate increased when H-245, H-248, H-291 or H-297 are
CC         mutated. {ECO:0000269|Ref.1};
CC       pH dependence:
CC         Optimum pH is 5.0. {ECO:0000269|Ref.3};
CC   -!- SUBCELLULAR LOCATION: Plastid, chloroplast thylakoid membrane
CC       {ECO:0000269|Ref.3, ECO:0000269|Ref.4}; Peripheral membrane protein
CC       {ECO:0000269|Ref.3, ECO:0000269|Ref.4}; Lumenal side
CC       {ECO:0000269|Ref.3, ECO:0000269|Ref.4}. Note=Binds to the thylakoid
CC       membrane at pH 5.2 and is released in the lumen at pH 7.2.
CC       {ECO:0000269|Ref.3}.
CC   -!- PTM: Disulfide bonds. Reduction of the disulfides results in loss of a
CC       rigid structure, a decrease in thermal stability of 15 degrees Celsius
CC       and a loss of activity. {ECO:0000269|PubMed:25764016}.
CC   -!- MISCELLANEOUS: The amount of VDE in vivo is estimated to be 1 molecule
CC       per 20-100 electron transport chains. {ECO:0000305|Ref.2}.
CC   -!- SIMILARITY: Belongs to the calycin superfamily. Lipocalin family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ250433; CAB59211.2; -; mRNA.
DR   SMR; Q9SM43; -.
DR   PRIDE; Q9SM43; -.
DR   KEGG; ag:CAB59211; -.
DR   OrthoDB; 489088at2759; -.
DR   BRENDA; 1.10.99.3; 5812.
DR   GO; GO:0009535; C:chloroplast thylakoid membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046422; F:violaxanthin de-epoxidase activity; IEA:UniProtKB-EC.
DR   Gene3D; 2.40.128.20; -; 1.
DR   InterPro; IPR012674; Calycin.
DR   InterPro; IPR010788; VDE.
DR   Pfam; PF07137; VDE; 1.
DR   SUPFAM; SSF50814; SSF50814; 1.
PE   1: Evidence at protein level;
KW   Chloroplast; Coiled coil; Direct protein sequencing; Disulfide bond;
KW   Membrane; Oxidoreductase; Plastid; Thylakoid; Transit peptide.
FT   TRANSIT         1..?
FT                   /note="Chloroplast"
FT   TRANSIT         ?..124
FT                   /note="Thylakoid"
FT                   /evidence="ECO:0000269|Ref.2"
FT   CHAIN           125..472
FT                   /note="Violaxanthin de-epoxidase, chloroplastic"
FT                   /id="PRO_0000273251"
FT   COILED          379..462
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        131..174
FT                   /note="Cys-rich"
FT   DISULFID        133..151
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   DISULFID        138..145
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   DISULFID        157..174
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   DISULFID        161..170
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   DISULFID        189..196
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   DISULFID        242..372
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         131
FT                   /note="C->S: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         133
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         138
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         145
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         151
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         157
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         161
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         170
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         174
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         189
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         196
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         242
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
FT   MUTAGEN         245
FT                   /note="H->A: 55% loss of activity; when associated with A-
FT                   248. Total loss of activity; when associated with A-248; A-
FT                   291 and R-297."
FT                   /evidence="ECO:0000269|Ref.1"
FT   MUTAGEN         245
FT                   /note="H->R: Total loss of activity; when associated with
FT                   R-248. Total loss of activity; when associated with R-248;
FT                   R-291 and R-297."
FT                   /evidence="ECO:0000269|Ref.1"
FT   MUTAGEN         248
FT                   /note="H->A: 40% loss of activity. 55% loss of activity;
FT                   when associated with A-245. Total loss of activity; when
FT                   associated with A-245; A-291 and R-297."
FT                   /evidence="ECO:0000269|Ref.1"
FT   MUTAGEN         248
FT                   /note="H->R: No effect. Total loss of activity; when
FT                   associated with R-245. Total loss of activity; when
FT                   associated with R-245; R-291 and R-297."
FT                   /evidence="ECO:0000269|Ref.1"
FT   MUTAGEN         291
FT                   /note="H->A: 99% loss of activity. Total loss of activity;
FT                   when associated with A-245; A-248 and A-297."
FT                   /evidence="ECO:0000269|Ref.1"
FT   MUTAGEN         291
FT                   /note="H->R: 55% loss of activity; when associated with R-
FT                   297. Total loss of activity; when associated with R-245; R-
FT                   248 and R-297."
FT                   /evidence="ECO:0000269|Ref.1"
FT   MUTAGEN         297
FT                   /note="H->R: 55% loss of activity; when associated with R-
FT                   291. Total loss of activity; when associated with R-245; R-
FT                   248 and R-291. Total loss of activity; when associated with
FT                   A-245; A-248 and A-291."
FT                   /evidence="ECO:0000269|Ref.1"
FT   MUTAGEN         372
FT                   /note="C->S: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:25764016"
SQ   SEQUENCE   472 AA;  53667 MW;  03C48EDE108BEEDB CRC64;
     MALVARSICV SYDEIAGICN NVSHRNFKKW VQWKNPFLFQ DDARRNIRFN DRKLSCTKFI
     GASEKLQHSK SPKSGLISCG WEVNSSKVVS NAVIPKKWNL LKLKVVEVTA IVACTFFVMS
     SAQAVDALKT CTCLLKECRI ELAKCIANPS CAANVACLQT CNNRPDETEC QIKCGDLFAN
     KVVDEFNECA VSRKKCVPQK SDVGEFPVPD PSVLVKSFNM ADFNGKWFIS SGLNPTFDAF
     DCQLHEFHLE DGKLVGNLSW RIKTPDGGFF TRTAVQKFAQ DPSQPGMLYN HDNAYLHYQD
     DWYILSSKIE NQPDDYVFVY YRGRNDAWDG YGGAFLYTRS ATVPENIVPE LNRAAQSVGK
     DFNKFIRTDN TCGPEPPLVE RLEKTVEEGE RTIIKEVEQL EGEIEGDLEK VGKTEMTLFQ
     RLLEGFQELQ KDEEYFLKEL NKEERELLED LKMEAGEVEK LFGRALPIRK LR
//
